Sungchen Liu

Dr. Sungchen Liu


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Journal of the Formosan Medical Association
Verified
Journal Article
Closed access
CWChao-Hung Wang
Chao-Hung Wang
CLChing-Hsiang Leung
Ching-Hsiang Leung
SLSungchen Liu
Sungchen Liu
CCCheng-Ho Chung
Cheng-Ho Chung

30 October 2024 in Hepatology Communications
Verified
Journal Article
Open access
JHJee-Fu Huang
Jee-Fu Huang
TCTien-Jyun Chang
Tien-Jyun Chang
MYMing-Lun Yeh
Ming-Lun Yeh
FSFeng Chih Shen
Feng Chih Shen
CTChi‐Ming Tai
Chi‐Ming Tai
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting >30% of the global population. Metabolic dysregulation, particularly insulin resistance and its subsequent manifestation as type 2 diabetes mellitus, serves as the fundamental pathogenesis of metabolic liver disease. Clinical evidence of the recent nomenclature evolution is accumulating. The interaction and impacts are bidirectional between MASLD and diabetes in terms of disease course, risk, and prognosis. Therefore, there is an urgent need to highlight the multifaceted links between MASLD and diabetes for both hepatologists and diabetologists. The surveillance strategy, risk stratification of management, and current therapeutic achievements of metabolic liver disease remain the major pillars in a clinical care setting. Therefore, the Taiwan Association for the Study of the Liver (TASL), Taiwanese Association of Diabetes Educators, and Diabetes Association of the Republic of China (Taiwan) collaboratively completed the first guidance in patients with diabetes and MASLD, which provides practical recommendations for patient care.

7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JLJiun‐Lu Lin
Jiun‐Lu Lin
SLSungchen Liu
Sungchen Liu
TLTze‐Fan Liu
Tze‐Fan Liu
SCShih-Ming Chuang
Shih-Ming Chuang
CHChun‐Ta Huang
Chun‐Ta Huang
Chung-Lieh HungChung-Lieh Hung
Chung-Lieh Hung
Background: Dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, is an epochal oral antidiabetic drug that improves cardiorenal outcomes. However, the effect of early dapagliflozin intervention on left ventricular (LV) remodeling in patients with type 2 diabetes free from cardiovascular disease remains unclear. Methods and Results: The ELUCIDATE trial was a prospective, open‐label, randomized, active‐controlled study that enrolled 76 patients with asymptomatic type 2 diabetes with LV ejection fraction ≥50%, randomized to the dapagliflozin 10 mg/day add‐on or standard‐of‐care group. Speckle‐tracking echocardiography–based measurements of the cardiac global longitudinal strain were performed at baseline and 24 weeks after treatment initiation. Patients who received dapagliflozin had a greater reduction in LV dimension (1.68 mm [95% CI, 0.53–2.84]; P =0.005), LV end‐systolic volume (5.51 mL [95% CI, 0.86–10.17]; P =0.021), and LV mass index (4.25 g/m 2.7 [95% CI, 2.42–6.09]; P <0.0001) compared with standard of care in absolute mean differences. Dapagliflozin add‐on therapy led to a significant LV global longitudinal strain increment (0.74% [95% CI, 1.00–0.49]; P <0.0001) and improved LV systolic and early diastolic strain rates (0.27/s [95% CI, 0.17–0.60]; and 0.11/s [95% CI, 0.06–0.16], respectively; both P <0.0001) but not in global circumferential strain. No significant changes were found in insulin resistance, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) levels, or other biomarkers at 6 months after the dapagliflozin administration. Conclusions: Dapagliflozin add‐on therapy could lead to more favorable cardiac remodeling accompanied by enhanced cardiac mechanical function among patients with asymptomatic type 2 diabetes. Our findings provide evidence of the efficacy of dapagliflozin use for the primary prevention of diabetic cardiomyopathy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03871621.

18 July 2022 in Archives of Medical Science
Verified
Journal Article
Closed access
SCShih-Ming Chuang
Shih-Ming Chuang
KNKat-Yien Ngu
Kat-Yien Ngu
CLChun-Chuan Lee
Chun-Chuan Lee
SCShih-Ming Chuang
Shih-Ming Chuang
YHYueh-Chiu Huang
Yueh-Chiu Huang
SLSungchen Liu
Sungchen Liu
Introduction: Male patients with type 2 diabetes (T2D) have a high prevalence of low testosterone (LT) or metabolic syndrome (MetS). While LT or MetS are associated with arterial stiffness, few studies have investigated the effect of these conditions when manifested together. Our study was performed to explore the influence of coexistence of LT and MetS on arterial stiffness in male patients with T2DM.Material and methods: We recruited 332 male patients with T2D at the endocrine and metabolic clinic of the Taitung branch of the Mackay Memorial hospital. Subjects were divided according to the presence of LT or MetS as follows: normal (neither condition present), LT only, MetS only and the coexistence of LT and MetS. All enrolled subjects consecutively underwent brachial-ankle pulse wave velocity (PWV) to evaluate arterial stiffness.Results: Patients with LT have a higher prevalence of MetS than those without LT (80.1% vs. 64.2%; P=0.03). Age, weight, triglycerides and PWV were significantly higher in patients with coexisting LT and MetS than in the groups with LT or MetS alone. Multiple linear regression analysis was performed to demonstrate that PWV was significantly positively associated with age (P <0.001), SBP (P=0.002) and triglycerides (P=0.001) and negatively associated with testosterone (P=0.039). ANCOVA analysis revealed that PWV remained highest in patients with coexisting MetS and LT compared to the other groups, even after adjusting for confounding factors.Conclusions: In our study, the coexistence of MetS and LT was significantly associated with a high risk of increased arterial stiffness in male patients with T2D.